Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.90 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.90 |
| ▸ | GAA | P10253 | 6/20 | 0.90 |
| ▸ | NPC1 | O15118 | 6/20 | 0.90 |
| ▸ | RAB9A | P51151 | 6/20 | 0.90 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.90 |
| ▸ | GLA | P06280 | 4/20 | 0.90 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.90 |
| ▸ | HPGD | P15428 | 3/20 | 0.90 |
| ▸ | POLB | P06746 | 3/20 | 0.90 |
| ▸ | PKM | P14618 | 2/20 | 0.90 |
| ▸ | TP53 | P04637 | 2/20 | 0.90 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.90 |
| ▸ | CASP1 | P29466 | 1/20 | 0.90 |
| ▸ | CASP7 | P55210 | 1/20 | 0.90 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.90 |
| ▸ | MEN1 | O00255 | 3/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.81 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.69 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11749206 | 0.95 | MAPT (1.00) | MAPTKDM4EGAANPC1RAB9A | |
| SCHEMBL3194266 | 0.90 | MAPT (1.00) | MAPTKDM4EGAANPC1RAB9A | |
| SCHEMBL6854930 | 0.87 | MAPT (0.96) | MAPTKDM4EGAANPC1RAB9A | |
| SCHEMBL1995933 | 0.86 | MAPT (1.00) | MAPTKDM4EGAANPC1RAB9A | |
| SCHEMBL5595585 | 0.84 | KDM4E (0.65) | MAPTKDM4EGAANPC1RAB9A | |
| SCHEMBL14111249 | 0.83 | MAPT (0.78) | MAPTKDM4EGAANPC1RAB9A | |
| SCHEMBL11778594 | 0.83 | MAPT (0.70) | MAPTKDM4EGAANPC1RAB9A | |
| Hydrochloric Acid SCHEMBL22130206 | 0.82 | MAPT (0.68) | MAPTKDM4EGAANPC1RAB9A | |
| Hydrochloric Acid SCHEMBL31219259 | 0.82 | MAPT (0.68) | MAPTKDM4EGAANPC1RAB9A | |
| SCHEMBL6401979 | 0.81 | MAPT (0.77) | MAPTKDM4EGAANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070259887-A1 | INHIBITORS OF POLYQ-AGGREGATION | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2007-11-08 | — | — | US | claimed |
| EP-1416931-B1 | INHIBITORS OF POLYQ-AGGREGATION | MAX PLANCK GESELLSCHAFT (DE) | 2007-06-13 | — | — | EP | claimed |
| US-20050124631-A1 | Inhibitors of polyq-aggregation | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2005-06-09 | — | — | US | claimed |
| EP-1416931-A1 | INHIBITORS OF POLYQ-AGGREGATION | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2004-05-12 | — | — | EP | claimed |
| WO-2003015772-A1 | INHIBITORS OF POLYQ-AGGREGATION | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2003-02-27 | — | — | WO | claimed |
| US-20070259887-A1 | INHIBITORS OF POLYQ-AGGREGATION | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2007-11-08 | — | — | US | disclosed |
| EP-1416931-B1 | INHIBITORS OF POLYQ-AGGREGATION | MAX PLANCK GESELLSCHAFT (DE) | 2007-06-13 | — | — | EP | disclosed |
| US-20050124631-A1 | Inhibitors of polyq-aggregation | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2005-06-09 | — | — | US | disclosed |
| EP-1416931-A1 | INHIBITORS OF POLYQ-AGGREGATION | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2004-05-12 | — | — | EP | disclosed |
| WO-2003015772-A1 | INHIBITORS OF POLYQ-AGGREGATION | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259887-A1 | INHIBITORS OF POLYQ-AGGREGATION | HTT, ATXN2, ATXN2L | MAPT 26/4885KDM4E 2734/4885GAA 243/4885 |
| US-20050124631-A1 | Inhibitors of polyq-aggregation | HTT, ATXN2, ATXN2L | MAPT 26/4885KDM4E 2734/4885GAA 243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.